Moreover, in an open-label evaluator-blinded clinical study, gender-dependent effects were observed in the neuroprotection of oral minocycline (a putative PARP inhibitor) treatment in the ischemic stroke (Amiri-Nikpour et al., 2015). Here, PARP1 is linked to ischemic stroke.